HDAC9 and AL amyloidosis: To date, five PI3K inhibitors (Copanlisib, Idelalisib, Umbralisib, Duvelisib, and Alpelisib) and four HDAC inhibitors (Romidepsin, Vorinostat, Belinostat, and Panobinostat) received FDA approval for treating different types of leukemia and lymphoma, multiple myeloma, and breast cancer [28,29].